INVENTION –

On page 26, please delete line 3 and insert therefore:

-- WHAT IS CLAIMED IS: --

Amendments to the Claims:

Please amend claims 1 to 9 and add claim 29 to 45 as set forth hereinafter.

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A combined agent, said agent comprising *cis*-hydroxyproline (CHP) and gemcitabine or capecitabine.

2. (Currently Amended) The agent according to claim 1,
~~characterized in that~~
~~it comprises~~ further comprising a pharmaceutically acceptable carrier, adjuvant and/or vehicle.

3. (Currently Amended) The agent according to claim 2,
~~characterized in that~~
wherein the carrier is selected from the group ~~comprising~~ consisting of fillers, diluents, binders, humectants, disintegrants, dissolution retarders, absorption enhancers, wetting agents, adsorbents, ~~and/or~~ lubricants and combinations thereof.

4. (Currently Amended) The agent according to claim 2,
~~characterized in that~~
wherein the ~~vehicles are~~ vehicle is selected from the group ~~comprising~~ consisting of liposomes, siosomes, ~~and/or~~ niosomes and combinations thereof.

5. (Currently Amended) The agent according to ~~any of claims 1 to 4~~ claim 1,
~~characterized in that~~
wherein the agent is a gel, poudrage, powder, infusion solution, tablet, sustained-release tablet, premix, a prodrug, emulsion, brew-up formulation, drops, a concentrate, granulate,

syrup, pellet, bolus, capsule, aerosol, spray and/or inhalant.

6. (Currently Amended) The agent according to claim 5,
~~characterized in that~~
wherein the CHP and gemcitabine are present in a formulation at a concentration of 0.1 to 99.5, preferably 0.5 to 95, and more preferably 20 to 80 wt.%.

7. (Currently Amended) The agent according to ~~any of claims 1 to 6~~ claim 1,
~~characterized in that~~
wherein the CHP and gemcitabine are present in said formulation at a ratio of from 500:1 to 1:500, preferably from 100:1 to 1:100, and more preferably from 50:1 to 1:50.

8. (Currently Amended) An anti-tumor agent,
~~characterized in that~~
~~it comprises~~ comprising a combined agent according to claim 1 ~~any of claims 1 to 7~~.

9.-28. (Cancelled)

29. (New) A method for prophylaxis, therapy, follow-up and/or aftercare of diseases associated with cell growth, cell differentiation and/or cell division comprising
administering to a person benefiting from such prophylaxis, therapy, follow-up and/or aftercare the agent of claim 1 in a prophylaxis, therapy, follow-up and/or aftercare effective amount.

30. (New) The method of claim 29, wherein the disease is a tumor.

31. (New) The method of claim 30, wherein tumor growth, tumor spreading, tumor angiogenesis, tumor invasion, tumor infiltration and/or tumor metastasization is inhibited or prevented.

32. (New) The method of claim 30, wherein the tumor is a neoplastic tumor, inflammatory tumor and/or an abscess, effusion and/or edema.

33. (New) The method of claim 30, wherein the tumor is a solid tumor or leukemia.

34. (New) The method of claim 33, wherein the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.

35. (New) The method of claim 30, wherein the tumor is a colon carcinoma, stomach carcinoma, pancreas carcinoma, small intestine carcinoma, ovarian carcinoma, cervical carcinoma, lung carcinoma, prostate carcinoma, mammary carcinoma, renal cell carcinoma, a brain tumor, head-throat tumor, liver carcinoma, and/or a metastase of the above tumors.

36. (New) The method of claim 33, wherein the solid tumor is a mammary, bronchial, colorectal, and/or prostate carcinoma and/or a metastase of the above tumors.

37. (New) The method of claim 34, wherein the tumor of the urogenital tract is a bladder carcinoma and/or a metastase of such tumors.

38. (New) The method of claim 29, wherein said follow-up is monitoring the effectiveness of an anti-tumor treatment.

39. (New) A method for the prophylaxis, prevention, diagnosis, attenuation, therapy, follow-up and/or aftercare of tumor metastasization, tumor invasion, tumor growth, tumor spreading, tumor infiltration and/or tumor angiogenesis comprising
administering to a person benefiting from such prophylaxis, prevention, diagnosis, attenuation, therapy, follow-up and/or aftercare the agent of claim 1 in a prophylaxis, prevention, diagnosis, attenuation, therapy, follow-up and/or aftercare effective amount.

40. (New) The method of claim 39, wherein said follow-up is monitoring the effectiveness of an anti-tumor treatment.

41. (New) The method of claim 29, wherein the agent is used in a combination therapy.

42. (New) The method of claim 39, wherein the agent is used in a combination therapy.

43. (New) The method of claim 42, wherein said combination therapy comprises a chemotherapy, a treatment with cytostatic agents and/or a radiotherapy.

44. (New) The method of claim 41, wherein the combination therapy comprises an adjuvant, biologically specified form of therapy.

45. (New) The method of claim 44, wherein said form of therapy is an immune therapy.

46. (New) A method for increasing sensitivity of tumor cells to cytostatic agents and/or radiation comprising
administering to a person benefiting from the increasing of the sensitivity the agent of claim 1 in a sensitivity of tumor cells to cytostatic agents and/or radiation increasing amount.

47. (New) A method for inhibiting viability, proliferation rate of cells for inducing apoptosis and/or cell cycle arrest comprising
administering to a person benefiting from such inhibiting the agent of claim 1 in an apoptosis and/or cell cycle arrest inducing amount.

48. (New) The method of claims 29, 39, 46 or 47, wherein the agent is administered orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, regionally and/or topically.

49. (New) The method of claims 29, 39, 46 or 47, wherein the agent is administered in overall amounts of from 0.05 to 1000 mg per kg, preferably from 5 to 450 mg per kg body weight per 24 hours.